-+ 0.00%
-+ 0.00%
-+ 0.00%

COGENT BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW FOR BEZUCLASTINIB IN COMBINATION WITH SUNITINIB FOR PATIENTS WITH GIST

Reuters·05/28/2026 12:00:07

Please log in to view news